The present invention is based on the discovery that by administering a predetermined dosing regimen of a pharmaceutical composition that comprises a bi-specific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X, it is possible to more effectively prevent and/or treat a disease that develops or progresses as a result of a decrease or loss of the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII.本發明發現藉由以規定的投藥方案投藥包含辨識第IX凝血因子及/或活化的第IX凝血因子以及第X凝血因子及/或活化的第X凝血因子的雙特異性抗原結合分子的醫藥組成物，可更有效果地預防及/或治療因第VIII凝血因子及/或活化的第VIII凝血因子的活性的降低或欠缺而發病及/或進展的疾病。
